• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORCYM CANADA CORP. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORCYM CANADA CORP. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVE Back to Search Results
Model Number PVS27
Medical Device Problem Code Patient-Device Incompatibility (2682)
Health Effect - Clinical Code Heart Block (4444)
Date of Event 04/06/2023
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The manufacturer is following up with the site to retrieve further information regarding this event and the device involved.A follow up report will be provided upon receipt of any further information.H3 other text : device remains implanted.
 
Event or Problem Description
The manufacturer was informed that on (b)(6) 2023 a patient was implanted with a perceval size xl valve.There was concomitant cabg surgery performed (1 vessel).The patient was in sinus rhythm post-operatively but was put under temporary pacemaker as per hospital protocol.Corcym representative was informed on (b)(6) 2023 that the patient was unable to get off temporary pacing and was scheduled for a permanent pacemaker implant.
 
Event or Problem Description
The manufacturer was informed that on (b)(6) 2023 a patient was implanted with a perceval size xl valve due to stenosis of the native valve leaflets.There was concomitant cabg surgery performed (1 vessel).The patient was in sinus rhythm post-operatively but was put under temporary pacemaker as per hospital protocol.Corcym representative was informed on (b)(6) 2023 that the patient was unable to get off temporary pacing and was scheduled for a permanent pacemaker implant.As per additional iformation received, permanent pacemaker was implanted on (b)(6) 2023 with no complications.As per medical judgement received, it's possible that the patient sinus rhythm will recover, hence the patient will be monitored by the cardiologists accordingly.The site didn't identify any procedural factors that may have contributed to the event.The patient's medical history and relevant risk factors, including a history of conduction disorders, are unknown and no information was shared with the manufacturer on patient's medication.It was reported that after implant the valve showed good flow, no regurgitation and improved lower mean and peak pressure gradients.No device malfunction is reported by the surgeon.
 
Additional Manufacturer Narrative
Updated fields: a2, b2, b5, g3, h2, h6, h10.The manufacturing and material records for the perceval heart valve and stent, model #icv1211, s/n # (b)(6), as they pertain to the reported event, were retrieved and reviewed by manufacture¿s quality engineering.The results confirmed that this valve satisfied all material, visual, and performance standards required for a (model #icv1211) perceval heart valve at the time of manufacture and release.Since the device remains implanted in the patient, no further investigation can be performed.No device malfunction has been reported by the site though and there is no evidence that the device didn't meet the specifications.Conduction disorders are common in patients with aortic valve diseases.As a result, it is common for patients to receive permanent pacemaker implantation after aortic valve replacement.Risk factors include preexisting conducting disease and preoperative aortic regurgitation.This event is, therefore, a known, inherent risk of the procedure, and it is listed among the potential adverse events in the perceval ifu.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PERCEVAL SUTURELESS AORTIC HEART VALVE
Common Device Name
TISSUE HEART VALVE
Manufacturer (Section D)
CORCYM CANADA CORP.
5005 north fraser way
burnaby, bc V5J 5 M1
CA  V5J 5M1
Manufacturer (Section G)
CORCYM CANADA CORP.
5005 north fraser way
burnaby, bc V5J 5 M1
CA   V5J 5M1
Manufacturer Contact
laura mannino
5005 north fraser way
burnaby, bc V5J 5-M1
CA   V5J 5M1
MDR Report Key16924964
Report Number3004478276-2023-00146
Device Sequence Number6805354
Product Code LWR
UDI-Device Identifier00896208000443
UDI-Public(01)00896208000443(240)ICV1211(17)260826
Combination Product (Y/N)N
Initial Reporter CountrySF
PMA/510(K) Number
P150011
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2023
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Health Professional,Company Representative,Distributor
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 06/14/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date08/26/2026
Device Model NumberPVS27
Device Catalogue NumberICV1211
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 04/14/2023
Supplement Date Received by Manufacturer05/15/2023
Initial Report FDA Received Date05/12/2023
Supplement Report FDA Received Date06/14/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured08/26/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Other; Required Intervention;
Patient Age67 YR
Patient SexMale
-
-